eGnome announced its successful development of next-generation therapeutic probiotics utilizing CRISPR-Cas9 gene-editing technology. The company overcame three major technical challenges, creating a probiotic that promotes GABA secretion, a neurotransmitter known to aid in stress relief and potentially support treatments for hypertension and diabetes. eGnome's CEO, Seoae Cho, stated that this breakthrough signifies a major advancement in the field of probiotic therapeutics.